<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230919059473N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-09</date_registration>
      <primary_sponsor>Rafsanjan University of Medical Sciences</primary_sponsor>
      <public_title>effect of topical Boswellia oil on pain severity in patients with lumbar disc herniation</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of topical Boswellia oil on pain severity in patients with lumbar disc herniation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72755</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sampling method was accessible and randomly assigned to groups, classified based on important intervening variables, including pain score at the time of entering the study and gender. The number of samples in the groups was equal. In order to control the confounding factors and ensure the same number of samples in the groups, the random minimization method was used (table below). The first and second samples were randomly entered into the groups, and in the rest of the cases, attention was paid to the sum of the indicators in the groups. Sampling continued until the desired sample volume was reached, Blinding description: The patients were completely unaware of which intervention group they were in. But they were aware of participating in the intervention.</study_design>
      <phase>1</phase>
      <hc_freetext>Patients with lumbar disc herniation.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, 30 ml droppers containing 10% frankincense oil (prepared in the laboratory of the Faculty of Iranian Medicine, Kerman University of Medical Sciences) for topical use were provided to the patients. The patients were taught to use 10 drops (Razavi et al., 2019) of frankincense oil topically, twice a day for 6 weeks. It was explained to the patients that they should first massage the pain area a little and when they feel heat, put the oil on the massage area for a maximum of one minute. If the patient himself is not able to use the oil in the pain area, the second person should do it for him. Intervention 2: In the control group, olive oil was used as a placebo in the pain area. 30 ml droppers containing olive oil, in the same packaging, (prepared in the laboratory of the Faculty of Iranian Medicine, Kerman University of Medical Sciences) for topical use, were provided to patients in the placebo group. The method of use is similar to the conditions of using frankincense oil. It was emphasized to the patient to use the drops without interruption and at specified intervals. To reduce the possibility of forgetting, the patients were asked to use the oil at the same times and set a reminder on their mobile phones to remind them when to use the drops. The number of times and how the oil was consumed was tracked by the researcher once a week by phone and recorded in the relevant form.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Tavakoli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central organization - Imam Ali Boulevard - Rafsanjan</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7717933777</zip>
        <telephone>+98 34 3428 0038</telephone>
        <email>fatemetavakoli1998@gmail.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Shahin Heidari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central organization - Imam Ali Boulevard - Rafsanjan University of Medical Sciences</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7717933777</zip>
        <telephone>+98 34 3428 0038</telephone>
        <email>kermanshah3252@yahoo.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 20 and 60 years
Not suffering from nervous and mental diseases
Lumbar disc herniation based on neurologist and MRI diagnosis
Lack of sensitivity to frankincense oil
Not having wounds and lesions at the place of use
Absence of diabetes mellitus
Absence of absolute rest
Absence of immune system problems in a person such as lupus erythematosus, multiple sclerosis (MS)
Not having a history of surgery in the back area
Absence of alcohol and drug addiction
Not using other complementary methods for pain relief
Not taking anticoagulants
Absence of pregnancy and breastfeeding
The amount of pain is more than 3 on the numerical-visual scale of VAS</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Desire to quit studying
The need for surgery during the study
The need to inject coronet during the study
Not performing intervention for more than two consecutive days or one alternate week
Change or exacerbation of back pain
Incidence of sensitivity and allergy during the implementation of the study, which is characterized by symptoms such as skin rashes.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M51.86</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other intervertebral disc disorders, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, 30 ml droppers containing 10% frankincense oil (prepared in the laboratory of the Faculty of Iranian Medicine, Kerman University of Medical Sciences) for topical use were provided to the patients. The patients were taught to use 10 drops (Razavi et al., 2019) of frankincense oil topically, twice a day for 6 weeks. It was explained to the patients that they should first massage the pain area a little and when they feel heat, put the oil on the massage area for a maximum of one minute. If the patient himself is not able to use the oil in the pain area, the second person should do it for him.</i_keyword>
      <i_keyword>In the control group, olive oil was used as a placebo in the pain area. 30 ml droppers containing olive oil, in the same packaging, (prepared in the laboratory of the Faculty of Iranian Medicine, Kerman University of Medical Sciences) for topical use, were provided to patients in the placebo group. The method of use is similar to the conditions of using frankincense oil. It was emphasized to the patient to use the drops without interruption and at specified intervals. To reduce the possibility of forgetting, the patients were asked to use the oil at the same times and set a reminder on their mobile phones to remind them when to use the drops. The number of times and how the oil was consumed was tracked by the researcher once a week by phone and recorded in the relevant form.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Evaluation of the effect of frankincense oil on pain: This study can show whether the local consumption of frankincense oil makes a significant change in the pain intensity of lumbar disc herniation patients. Timepoint: Immediately after the end of the intervention. Method of measurement: Visual Pain Scale Questionnaire (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rafsanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-03</approval_date>
        <contact_name>Research Ethics Committees of Rafsanjan University of Medical Sciences</contact_name>
        <contact_address>Rafsanjan University of Medical Sciences - Imam Ali Blvd Rafsanjan Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
